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ABSTRACT
Introduction: Diabetes mellitus (DM) is associ-
ated with multiple complications, including
cardiovascular diseases. Previously, it was
believed that the latter are mainly caused by
hypertension and increased systolic blood
pressure. However, recent studies have chal-
lenged this concept, by showing that diastolic
dysfunction may also be involved in the car-
diovascular events that are associated with DM.
Pharmacologic management of hypertension in
patients with type 2 DM appears to adversely
influence diastolic function.
Methods: Four hundred and eight medical
records of hypertensive and obese Emirati
patients with type 2 DM were included in the
present retrospective study. The main objectives
of the present study were (1) to determine the
prevalence of low diastolic blood pressure (DBP)
and diastolic hypotension in this group of
patients and (2) to investigate the associations,
if any, between the use of various antihyper-
tensive medications and low DBP and diastolic
hypotension.
Results: The results of the present study
showed that low DBP (\ 70 mmHg) was expe-
rienced by 40% of the hypertensive type 2 DM
patients, whereas diastolic hypotension
(\60 mmHg) was reported to occur in about
10% of the patients. Another important factor
that has been significantly correlated with
diastolic hypotension is age (p\ 0.01). Associ-
ation trends have been reported between low
DBP and diastolic hypotension and several
antihypertensive therapies, including (1)
monotherapies such as angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II
receptor blockers (ARBs), (2) dual therapies such
as ACE inhibitors in combination with thiazide-
like diuretics (THLDs) or beta blockers, and (3)
triple therapy combinations of ACE inhibitors
with THLDs and potassium-sparing diuretics.
Conclusion: The use of antihypertensive medi-
cations, in particular ACE inhibitors and ARBs,
appears to be a risk factor for the development
of low DBP and diastolic hypotension in obese
hypertensive Emirati patients with type 2 DM,
whereas calcium channel blockers seem to be a
safer option for this group of patients.
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INTRODUCTION
The challenge of treating hypertension in obese
patients with type 2 diabetes mellitus (T2DM)
has revolutionized the classic concept of meta-
bolic syndrome and redefined the relationship
between its major elements: obesity, insulin
resistance, and hypertension [1].
Hypertension is one of the major risk factors
for morbidity and mortality in the general
population, particularly in obese patients with
T2DM. The latter have a double chance of
developing hypertension compared to nondia-
betic subjects with normal weight [2, 3]. Most
(75%) T2DM patients die from cardiovascular
complications associated with hypertension
[4, 5]. In addition, well-documented evidence
has shown that obesity is a global epidemic and
is strongly related to the development of
hypertension and T2DM, emphasizing the
interaction between the components of meta-
bolic syndrome [6–9]. In good agreement with
corresponding international data, previous
studies performed in the Gulf region have
shown that there is a high prevalence of
hypertension among T2DM patients [10, 11].
Similarly, studies carried out in the United Arab
Emirates (UAE) have reported high prevalences
of DM, hypertension, and obesity in Emirati
and non-Emirati populations [12, 13]. The UAE
has experienced pronounced economic growth
during the past few decades, which has led to
increased prevalences of several risk factors for
DM, obesity, and hypertension.
Classically, the main therapeutic path to
controlling hypertension has been to decrease
the systolic blood pressure (SBP) (\140 mmHg)
[14]. More recent findings have challenged this
concept by demonstrating that a low diastolic
pressure (DBP) is strongly associated with car-
diovascular events, particularly myocardial
infarction [15]. The risk of the latter in patients
with a DBP of 60 mmHg was found to be
double that in patients with a DBP of
100 mmHg [16]. These findings raised concerns
regarding the effects of tight SBP control and
simultaneous low DBP on cardiovascular out-
comes. This leads to a very important question
about the optimal level of SBP and whether it
can be reached without increasing the inci-
dence of diastolic hypotension. The latter is
defined by several associations, including the
American College of Cardiology, as a DBP of
\60 mmHg [2, 3].
It is noteworthy that patients with DM and
hypertension have higher SBPs (2–3 mmHg)
and lower DBPs (1–3 mmHg) than nondiabetic
hypertensive patients. These findings, along
with the outcomes of the Hypertension Optimal
Treatment Study, have led to the development
of new therapeutic targets (\ 130/80 mmHg) for
treating hypertension in patients with DM
[17–19].
Therapy for hypertension in T2DM classi-
cally includes several subclasses of antihyper-
tensive medications, and data comparing the
outcomes of using each subclass are limited.
However, in general, it is evident that angio-
tensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers (ARBs), diuretics,
and beta blockers are superior to placebo.
Importantly, it has been shown that the appli-
cation of multiple combinations of these sub-
classes is strongly associated with a reduction in
the SBP [14].
Although diastolic hypotension in DM
patients is regarded as a major concern, the
effects of multiple antihypertensive medica-
tions on the DBP are yet to be identified and
reported. The literature lacks exhaustive studies
of the relationship between the incidence of
diastolic hypotension and the use of antihy-
pertensive medications, and the susceptibility
of obese patients with T2DM to diastolic
hypertension development. Taking into
account all of these findings and the points
made above, the study reported in the present
paper was designed (1) to determine the preva-
lence of diastolic hypotension in a cohort of
T2DM patients with hypertension and (2) to
investigate the associations, if any, between the
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use of antihypertensive medications, and low
DBP and/or diastolic hypotension.
METHODS
Data Source
The present work focuses on a single-center
retrospective longitudinal study conducted
between June 2016 and June 2017 at Rashid
Centre of Diabetes and Research (RCDR, Sheikh
Khalifa Medical City, Ajman, UAE). This article
is based on data that were extracted from elec-
tronic medical records and previously con-
ducted studies, and does not report any
interventional studies of human participants or
animals that were performed by any of the
authors.
All data were collected from an electronic
medical records system (Diamond Database
System). The following demographic, clinical,
and medication data were collected from the
medical records: age, age at diagnosis, gender,
diabetes duration, SBP, DBP, pulse, body mass
index (BMI), and hemoglobin A1c (HA1c). The
analysis also included the lipid profile: total
cholesterol, high-density lipoprotein (HDL),
low-density lipoprotein (LDL), triglycerides, and
antihypertensive medications.
Three thousand medical records of Emirati
patients with DM were reviewed, and 500
medical records were randomly selected and
screened. Those medical records were created by
consultant diabetologists and endocrinologists
who assessed the patients regularly. All patients
with DM attended the diabetes clinics in RCDR
on a quarterly basis (an initial visit and three
follow-up visits per annum).
Study Population
Emirati patients aged between 18 and 70 years
old with T2DM and hypertension were included
in the present study, and all patients visited the
diabetes clinic at least four times per annum.
Patients with type 1 DM and/or normal blood
pressure were excluded. Four hundred and eight
medical records were retrieved and included in
the study based on the inclusion and exclusion
criteria. The same group of patients were fol-
lowed up after the initial visit (visit 1, V1) at
visit 2 (6-month follow-up, V2), visit 3 (12-
month follow-up, V3), and visit 4 (18-month
follow-up, V4).
Outcomes Analysis
The primary aims of the study were to investi-
gate the presence of diastolic hypotension in
Emirati patients with hypertension and T2DM
and identify the relationships, if any, between a
low DBP or diastolic hypotension and the use of
various antihypertensive medications. The DBP
was categorized into four groups: normal DBP
([74 mmHg), low DBP (74–64 mmHg), dias-
tolic hypotension (63–54 mmHg), and severe
diastolic hypotension (\ 54 mmHg). These
groups were sample-based and statistically
derived using a mean DBP of 74 mmHg as a
reference point [1].
Statistical Analysis
All data are expressed as the mean (± SD) and
the number of patients (percentage) for con-
tinuous and discrete variables, respectively. An
assessment of the normality of the data was
conducted and a normal DBP distribution was
observed using a Q–Q plot. In addition, the chi-
square test and cross-tabulation were used to
investigate the relationships, if any, between
DBP and various antihypertensive medications.
Two-tailed p values of less than 0.05 were con-
sidered statistically significant. SPSS version
21.0 was used to carry out the statistical
analysis.
RESULTS
A total of 500 patients were randomly selected
between June 2016 and June 2017, and 92
patients were excluded based on the criteria set
prior to the screening procedure. Four hun-
dred and eight Emirati patients with T2DM and
hypertension were included in the study. Those
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patients visited RCDR diabetes clinic at least
four times: V1–V4.
As shown in Table 1, the average age of the
studied population was 61.0 ± 10.0 years, and
the majority of the patients (72%) were female.
In addition, the average age at diabetes diag-
nosis was 46.2 ± 10.9 years, the average dura-
tion of the disease was about 14.7 ± 7.5 years,
and the average initial HbA1c was 8.8 ± 2.0%.
The studied population had uncontrolled DM,
and the lowest HbA1c reported at V4 was
7.9 ± 1.5%.
Obesity was a common feature of this pop-
ulation, with an average BMI of 34.0 ± 8.2. A
slight decrease in BMI was observed during the
follow-up visits (V2, 33.8 ± 7.8; V3, 33.9 ± 8.2;
V4, 33.6 ± 7.8). The average lipid profile during
the initial visit was as follows: total cholesterol
4.4 ± 1.1, triglycerides 1.6 ± 0.9, HDL 1.2 ± 0.3,
and LDL 2.7 ± 0.9, and the average profile did
not significantly change during V2, V3, and V4.
SBP (142.0 ± 22.3 mmHg) was high during the
initial visit but decreased with each subsequent
visit, whereas the DBP was initially low (74.0 ±
12.34) and remained so at V2 (71.8 ± 10.0), V3
(73.1 ± 9.6), and V4 (72.8 ± 8.8); this decrease
in DBP across visits was statistically significant
(p\ 0.05).
The results of the present study show that a
low DBP (\ 70 mmHg) was experienced by 40%
of the hypertensive T2DM Emirati patients,
while diastolic hypotension (\60 mmHg) was
reported for 10% of these patients. Age was
found to be significantly correlated with dias-
tolic hypotension (p\0.01), and an inverse
relationship between DBP and age was
observed.
Different classes of antihypertensives were
used as monotherapies and in combined thera-
pies to control hypertension in this group of
patients. As shown in Table 2, eight antihyper-
tensive classes were used, including beta block-
ers, ACE inhibitors, ARBs, direct renin inhibitors
(DRIs), calcium channel blockers (CCBs), and
diuretics (loop diuretics, potassium-sparing
diuretics (PSDs), and thiazide-like diuretics
Table 1 Demographic and clinical data for the studied population throughout the four clinical visits
Variable Visit 1 Visit 2 Visit 3 Visit 4
Subjects (n) 408 – – –
Age (years) 61.0 ± 10.0 – – –
Gender
No. females, n (%) 292 (72) – – –
Age at diagnosis (years) 46.2 ± 10.9 – – –
Diabetes duration (years) 14.7 ± 7.5 – – –
BMI (kg/m2) 34.0 ± 8.2 33.8 ± 7.8 33.9 ± 8.2 33.6 ± 7.8
HbA1C (%) 8.8 ± 2.0 8.0 ± 1.6 8.0 ± 1.7 7.9 ± 1.5
Total cholesterol (mmol/L) 4.4 ± 1.1 4.1 ± 0.9 4.1 ± 1.0 4.1 ± 0.9
Triglycerides (mmol/L) 1.6 ± 0.9 1.6 ± 1.1 1.7 ± 1.0 1.7 ± 1.0
HDL (mg/dL) (mmol/L) 1.2 ± 0.3 1.1 ± 0.3 1.2 ± 0.3 1.1 ± 0.3
LDL (mg/dL) (mmol/L) 2.7 ± 0.9 2.4 ± 0.8 2.4 ± 0.8 2.4 ± 0.8
Systolic blood pressure 142.0 ± 22.3 137.4 ± 19.6 140.0 ± 22.6 140.9 ± 19.6
Diastolic blood pressure 74.0 ± 12.3 71.8 ± 10.0* 73.1 ± 9.6* 72.8 ± 8.8*
BMI body mass index, HbA1C hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein
*p\ 0.05
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(THLDs)). Aromatic L-amino acid decarboxylase
inhibitors and imidazoline receptor agonists
were rarely used as antihypertensive medica-
tions in the studied population, so they were
excluded from the analysis.
As shown in Table 3, the percentage of the
total number of patients using antihypertensive
monotherapy (V1, 39%) decreased slightly
across the visits (V2, 32%; V3, 29%; V4, 25%),
whereas dual antihypertensive medications
appear to have been used by approximately the
same percentage of patients across the visits
(V1, 36%; V2, 33%, V3, 32%; V4, 32%). In
contrast to the monotherapies, the use of triple
antihypertensive medications increased slightly
across the visits (V1, 24%; V2, 33%; V3, 38%;
V4, 43%). The percentage of patients with nor-
mal DBP ([70 mmHg) was comparable across
visits (V1, 48%; V2, 38%; V3, 43%; V4, 42%);
similarly, the percentage of patients with low
DBP (74–64 mmHg) and the percentage with
diastolic hypotension (63–54 mmHg) did not
change significantly across the visits. Severe
diastolic hypotension (\54 mmHg) was rarely
experienced by this group of patients: 3% was
the highest percentage of patients with severe
diastolic hypotension across the visits, as shown
in Table 3. Therefore, severe diastolic hypoten-
sion (\54 mmHg) was not included in our
analysis of the association between antihyper-
tensive medications subclasses and DBP. In
addition, normal DBP ([70 mmHg) was not
included in the analysis of the subclasses of
antihypertensive medications because this
analysis focused on low DBP and diastolic
hypotension.
The findings of the present study show that
although eight subclasses of antihypertensive
medications were used as monotherapies in this
cohort, only four of those subclasses (ACE inhi-
bitors, ARBs, beta blockers, and CCBs) were
chosen as initial treatments for hypertension
and used consistently throughout the follow-up
period (Table 4). Loop diuretics and DRIs were
also used as initial monotherapies but were
alternated during the follow-up period. In con-
trast, PSDs were used as a monotherapy during
the later visits. Association trends of ACE inhi-
bitors, ARBs, and beta blockers with lowDBP and
diastolic hypotension were observed across the
visits, and these association trends were partic-
ularly significant at V3 (p\0.05) (Table 4).
It has been observed that dual antihyper-
tensive therapy of ACE inhibitors in combina-
tion with THLDs or CCBs or beta blockers has a
strong tendency to cause a low DBP and dias-
tolic hypotension, and this association was
found to be very significant at V1 (p\ 0.01)
(Table 5). In addition, an association trend
between low DBP and diastolic hypotension
and ACE inhibitors combined with either ARBs
or loop diuretics was reported. This trend was
also observed for ACE inhibitors used in com-
bination with PSDs, but was confined to the last
visit only. Similarly, ARBs used in combination
with THLDs or CCBs or beta blockers or loop
diuretics appear to be significantly associated
with a low DBP and diastolic hypotension (V1,
p\0.01). As shown in Table 5, an association
trend between low DBP and ARBs in
Table 2 Classes of antihypertensive medications used by
the studied population
Antihypertensive medications
Class Medication
Beta blockers Atenolol, bisoprolol carvedilol
Angiotensin-converting
enzyme (ACE)
inhibitors
Perindopril, lisinopril
enalapril, cilazapril
fosinopril
Angiotensin II receptor
blocker (ARBs)
Indapamide, losartan
irbesartan, valsartan
telmisartan
Direct renin inhibitors
(DRIs)
Aliskiren
Calcium channel blockers
(CCBs)
Amlodipine, nifedipine
lercanidipine, verapamil,
felodipine
Potassium-sparing
diuretics (PSDs)
Hydrochlorothiazide,
spironolactone
Loop diuretics Furosemide
Thiazide-like diuretics
(THLDs)
Indapamide
Diabetes Ther (2018) 9:1853–1868 1857
T
ab
le
3
T
ot
al
nu
m
be
rs
an
d
pe
rc
en
ta
ge
s
of
pa
ti
en
ts
on
an
ti
hy
pe
rt
en
si
ve
m
ed
ic
at
io
ns
(m
on
ot
he
ra
py
or
du
al
or
tr
ip
le
th
er
ap
y)
at
ea
ch
cl
in
ic
al
vi
si
t,
an
d
su
m
m
ar
y
of
pa
ti
en
t
D
B
P
da
ta
at
ea
ch
vi
si
t
C
lin
ic
al
vi
si
ts
V
is
it
1
V
is
it
2
A
nt
ih
yp
er
te
ns
iv
e
th
er
ap
y
M
on
o-
th
er
ap
y
D
ua
l
th
er
ap
y
T
ri
pl
e
th
er
ap
y
T
ot
al
M
on
o-
th
er
ap
y
D
ua
l
th
er
ap
y
T
ri
pl
e
th
er
ap
y
T
ot
al
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
[
74
m
m
H
g
68
(4
3%
)
75
(5
1%
)
51
(5
2%
)
19
4
(4
8%
)
45
(3
3%
)
47
(3
5%
)
62
(4
6%
)
15
4
(3
8%
)
74
–6
4
m
m
H
g
45
(2
9%
)
46
(3
1%
)
25
(2
6%
)
11
6
(2
9%
)
53
(3
9%
)
46
(3
4%
)
51
(3
8%
)
15
0
(3
7%
)
63
–5
4
m
m
H
g
44
(2
8%
)
25
(1
8%
)
21
(2
2%
)
90
(2
2%
)
34
(2
6%
)
42
(3
0%
)
22
(1
6%
)
98
(2
4%
)
\
54
m
m
H
g
0
(0
%
)
0
(0
%
)
0
(0
%
)
0
(0
%
)
1
(1
%
)
1
(1
%
)
0
(0
%
)
2
(1
%
)
T
ot
al
15
7
(3
9%
)
14
6
(3
6%
)
97
(2
4%
)
40
0
(1
00
%
)
13
3
(3
2%
)
13
6
(3
3%
)
13
5
(3
3%
)
40
4
(1
00
%
)
C
lin
ic
al
vi
si
ts
V
is
it
3
V
is
it
4
A
nt
ih
yp
er
te
ns
iv
e
th
er
ap
y
M
on
o-
th
er
ap
y
D
ua
l
th
er
ap
y
T
ri
pl
e
th
er
ap
y
T
ot
al
M
on
o-
th
er
ap
y
D
ua
l
th
er
ap
y
T
ri
pl
e
th
er
ap
y
T
ot
al
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
[
74
m
m
H
g
42
(3
6%
)
59
(4
4%
)
74
(4
8%
)
17
5
(4
3%
)
31
(3
1%
)
59
(4
6%
)
80
(4
6%
)
17
0
(4
2%
)
74
–6
4
m
m
H
g
46
(3
9%
)
46
(3
4%
)
64
(4
1%
)
15
6
(3
8%
)
43
(4
3%
)
48
(3
8%
)
68
(4
0%
)
15
9
(3
9%
)
63
–5
4
m
m
H
g
25
(2
2%
)
25
(1
9%
)
14
(9
%
)
64
(1
6%
)
24
(2
4%
)
21
(1
6%
)
23
(1
3%
)
68
(1
7%
)
\
54
m
m
H
g
4
(3
%
)
2
(2
%
)
1
(1
%
)
7
(3
%
)
2
(2
%
)
0
(0
%
)
1
(1
%
)
3
(2
%
)
T
ot
al
11
7
(2
9%
)
13
2
(3
2%
)
15
3
(3
8%
)
40
2
(1
00
%
)
10
0
(2
5%
)
12
8
(3
2%
)
17
2
(4
3%
)
40
0
(1
00
%
)
1858 Diabetes Ther (2018) 9:1853–1868
T
ab
le
4
A
ss
oc
ia
ti
on
pa
tt
er
n
of
an
ti
hy
pe
rt
en
si
ve
m
on
ot
he
ra
py
w
it
h
lo
w
D
B
P
an
d
di
as
to
lic
hy
po
te
ns
io
n
in
T
2D
M
pa
ti
en
ts
C
lin
ic
al
vi
si
t
V
is
it
1
V
is
it
2
p
va
lu
e
0.
6
0.
7
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
A
nt
ih
yp
er
te
ns
iv
e
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
A
C
E
in
hi
bi
to
rs
20
.0
23
.1
26
.0
18
.9
23
.0
21
.3
17
.0
14
.4
A
R
B
s
15
.0
14
.9
14
.0
12
.2
19
.0
20
.2
15
.0
13
.6
B
et
a
bl
oc
ke
rs
6.
0
2.
5
2.
0
2.
1
4.
0
2.
2
1.
0
1.
5
C
C
B
s
1.
0
1.
1
0.
0
1.
1
4.
0
3.
3
1.
0
2.
2
PS
D
s
–
–
–
–
–
–
–
–
T
H
L
D
s
2.
0
1.
7
2.
0
1.
4
1.
0
1.
1
0.
0
0.
7
L
oo
p
di
ur
et
ic
s
0.
0
0.
3
0.
0
0.
2
–
–
–
–
D
R
Is
1.
0
0.
3
0.
0
0.
2
1.
0
0.
4
0.
0
0.
2
C
lin
ic
al
vi
si
t
V
is
it
3
V
is
it
4
p
va
lu
e
0.
03
*
0.
2
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
A
nt
ih
yp
er
te
ns
iv
e
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
A
C
E
in
hi
bi
to
rs
22
.0
20
.5
13
.0
8.
6
17
.0
17
.3
11
.0
7.
4
A
R
B
s
21
.0
19
.0
9.
0
7.
9
20
.0
16
.1
12
.0
6.
9
B
et
a
bl
oc
ke
rs
2.
0
1.
9
1.
0
0.
8
3.
0
2.
4
0.
0
1.
3
C
C
B
s
1.
0
2.
3
0.
0
0.
1
0.
0
0.
4
1.
0
0.
2
PS
D
s
–
–
–
–
1.
0
2.
0
0.
0
0.
9
T
H
L
D
s
2.
0
0.
1
0.
0
0.
2
1.
0
1.
2
0.
0
0.
5
L
oo
p
di
ur
et
ic
s
–
–
–
–
–
–
–
–
D
R
Is
0.
0
0.
4
1.
0
0.
2
–
–
–
–
Diabetes Ther (2018) 9:1853–1868 1859
T
ab
le
5
A
ss
oc
ia
ti
on
pa
tt
er
n
of
du
al
an
ti
hy
pe
rt
en
si
ve
th
er
ap
y
w
it
h
lo
w
D
B
P
an
d
di
as
to
lic
hy
po
te
ns
io
n
in
T
2D
M
pa
ti
en
ts
C
lin
ic
al
vi
si
t
V
is
it
1
V
is
it
2
p
va
lu
e
0.
00
*
0.
7
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
A
nt
ih
yp
er
te
ns
iv
es
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
A
C
E
in
hi
bi
to
rs
?
T
H
L
D
s
9.
0
10
.4
12
.0
8.
5
11
.0
11
.4
11
.0
7.
7
A
C
E
in
hi
bi
to
rs
?
C
C
B
s
6.
0
4.
8
3.
0
3.
9
3.
0
3.
3
1.
0
2.
2
A
R
B
s
?
C
C
B
s
6.
0
3.
7
3.
0
3.
0
6.
0
6.
3
3.
0
4.
2
A
C
E
in
hi
bi
to
rs
?
be
ta
bl
oc
ke
rs
5.
0
3.
9
3.
0
3.
2
6.
0
3.
7
3.
0
2.
5
A
R
B
s
?
be
ta
bl
oc
ke
rs
4.
0
2.
0
0.
0
1.
6
2.
0
3.
7
5.
0
2.
5
A
R
B
s
?
lo
op
di
ur
et
ic
s
4.
0
2.
3
0.
0
1.
8
5.
0
3.
3
3.
0
2.
4
A
R
B
s
?
PS
D
s
–
–
–
–
–
–
–
–
A
C
E
in
hi
bi
to
rs
?
A
R
B
s
3.
0
1.
1
0.
0
0.
9
0.
0
1.
8
2.
0
1.
2
A
R
B
s
?
T
H
L
D
s
3.
0
6.
8
4.
0
5.
5
9.
0
11
.4
8.
0
7.
7
B
et
a
bl
oc
ke
rs
?
C
C
B
s
2.
0
2.
3
0.
0
1.
8
1.
0
2.
2
3.
0
1.
5
A
C
E
in
hi
bi
to
rs
?
lo
op
di
ur
et
ic
s
1.
0
0.
8
1.
0
0.
7
1.
0
0.
4
0.
0
0.
2
T
H
L
D
s
?
be
ta
bl
oc
ke
rs
1.
0
1.
1
0.
0
0.
9
0.
0
0.
7
2.
0
0.
5
T
H
L
D
s
?
C
C
B
s
0.
0
0.
8
1.
0
0.
7
1.
0
0.
4
0.
0
0.
2
A
C
E
in
hi
bi
to
rs
?
PS
D
s
–
–
–
–
–
–
–
–
1860 Diabetes Ther (2018) 9:1853–1868
T
ab
le
5
co
nt
in
ue
d
C
lin
ic
al
vi
si
t
V
is
it
3
V
is
it
4
p
va
lu
e
0.
7
0.
7
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
A
nt
ih
yp
er
te
ns
iv
es
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
A
C
E
in
hi
bi
to
rs
?
T
H
L
D
s
10
.0
11
.2
5.
0
4.
7
11
.0
11
.7
4.
0
5.
0
A
C
E
in
hi
bi
to
rs
?
C
C
B
s
2.
0
4.
6
4.
0
1.
9
0.
0
0.
8
2.
0
0.
4
A
R
B
s
?
C
C
B
s
11
.0
7.
7
2.
0
3.
2
0.
0
0.
8
0.
0
0.
3
A
C
E
in
hi
bi
to
rs
?
be
ta
bl
oc
ke
rs
4.
0
3.
5
1.
0
1.
5
3.
0
3.
6
3.
0
1.
5
A
R
B
s
?
be
ta
bl
oc
ke
rs
1.
0
2.
7
1.
0
1.
1
7.
0
4.
0
1.
0
1.
7
A
R
B
s
?
lo
op
di
ur
et
ic
s
3.
0
1.
9
0.
0
0.
8
2.
0
1.
2
0.
0
0.
5
A
R
B
s
?
PS
D
s
–
–
–
–
6.
0
5.
6
1.
0
2.
4
A
C
E
in
hi
bi
to
rs
?
A
R
B
s
0.
0
0.
0
1.
0
0.
8
2.
0
1.
2
0.
0
0.
5
A
R
B
s
?
T
H
L
D
s
11
.0
12
.4
6.
0
5.
2
7.
0
12
.9
6.
0
5.
5
B
et
a
bl
oc
ke
rs
?
C
C
B
s
1.
0
1.
5
1.
0
0.
6
–
–
–
–
A
C
E
in
hi
bi
to
rs
?
lo
op
di
ur
et
ic
s
–
–
–
–
–
–
–
–
T
H
L
D
s
?
be
ta
bl
oc
ke
rs
0.
0
1.
2
1.
0
0.
5
1.
0
0.
8
1.
0
0.
3
T
H
L
D
s
?
C
C
B
s
–
–
–
–
–
–
–
–
A
C
E
in
hi
bi
to
rs
?
PS
D
s
–
–
–
–
4.
0
4.
0
0.
0
1.
7
Diabetes Ther (2018) 9:1853–1868 1861
T
ab
le
6
A
ss
oc
ia
ti
on
pa
tt
er
n
of
tr
ip
le
an
ti
hy
pe
rt
en
si
ve
th
er
ap
y
w
it
h
lo
w
D
B
P
an
d
di
as
to
lic
hy
po
te
ns
io
n
in
T
2D
M
pa
ti
en
ts
C
lin
ic
al
vi
si
t
V
is
it
1
V
is
it
2
p
va
lu
e
0.
9
0.
7
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
A
nt
ih
yp
er
te
ns
iv
es
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
A
C
E
in
hi
bi
to
rs
?
T
H
L
D
s
?
PS
D
s
–
–
–
–
–
–
–
–
A
R
B
s
?
T
H
L
D
s
?
PS
D
s
–
–
–
–
–
–
–
–
A
R
B
s
?
T
H
L
D
s
?
be
ta
bl
oc
ke
rs
1.
0
2.
5
1.
0
2.
1
–
–
–
–
A
R
B
s
?
PS
D
s
?
be
ta
bl
oc
ke
rs
–
–
–
–
0.
0
0.
4
1.
0
0.
2
A
C
E
in
hi
bi
to
rs
?
T
H
L
D
s
?
be
ta
bl
oc
ke
rs
1.
0
1.
4
2.
0
1.
2
4.
0
2.
9
1.
0
2.
0
A
R
B
s
?
A
C
E
in
hi
bi
to
rs
?
be
ta
bl
oc
ke
rs
1.
0
1.
1
1.
0
0.
9
2.
0
1.
5
0.
0
1.
0
A
C
E
in
hi
bi
to
rs
?
T
H
L
D
s
?
C
C
B
s?
4.
0
5.
1
4.
0
4.
1
9.
0
7.
4
4.
0
5.
0
A
R
B
s
?
C
C
B
s
?
be
ta
bl
oc
ke
rs
2.
0
2.
0
2.
0
1.
6
–
–
–
–
A
C
E
in
hi
bi
to
rs
?
A
R
B
s
?
C
C
B
s
1.
0
0.
6
0.
0
0.
5
2.
0
1.
1
0.
0
0.
7
A
C
E
in
hi
bi
to
rs
?
PS
D
s
?
be
ta
bl
oc
ke
rs
0.
0
0.
8
2.
0
0.
7
–
–
–
–
A
R
B
s
?
T
H
L
D
s
?
C
C
B
s
3.
0
3.
4
3.
0
2.
8
10
.0
7.
4
1.
0
5.
0
B
et
a
bl
oc
ke
rs
?
C
C
B
s
?
lo
op
di
ur
et
ic
s
1.
0
0.
3
0.
0
0.
2
–
–
–
–
A
R
B
s
?
PS
D
s
?
lo
op
di
ur
et
ic
s
0.
0
0.
3
1.
0
0.
2
0.
0
0.
7
2.
0
0.
5
1862 Diabetes Ther (2018) 9:1853–1868
T
ab
le
6
co
nt
in
ue
d
C
lin
ic
al
vi
si
t
V
is
it
3
V
is
it
4
p
va
lu
e
0.
4
0.
00
*
D
ia
st
ol
ic
bl
oo
d
pr
es
su
re
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
74
–6
4
m
m
H
g
63
–5
4
m
m
H
g
A
nt
ih
yp
er
te
ns
iv
es
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
N
o.
pa
ti
en
ts
E
xp
ec
te
d
no
.
pa
ti
en
ts
A
C
E
in
hi
bi
to
rs
?
T
H
L
D
s
?
PS
D
s
–
–
–
–
8.
0
6.
4
0.
0
2.
7
A
R
B
s
?
T
H
L
D
s
?
PS
D
s
–
–
–
–
10
.0
10
.9
3.
0
4.
6
A
R
B
s
?
T
H
L
D
s
?
be
ta
bl
oc
ke
rs
10
.0
6.
2
1.
0
2.
6
8.
0
7.
2
2.
0
3.
1
A
R
B
s
?
PS
D
s
?
be
ta
bl
oc
ke
rs
1.
0
0.
4
0.
0
0.
2
6.
0
4.
4
1.
0
1.
9
A
C
E
in
hi
bi
to
rs
?
T
H
L
D
s
?
be
ta
bl
oc
ke
rs
4.
0
4.
3
1.
0
1.
8
4.
0
3.
6
0.
0
1.
5
A
R
B
s
?
A
C
E
in
hi
bi
to
rs
?
be
ta
bl
oc
ke
rs
2.
0
1.
5
0.
0
0.
6
3.
0
2.
0
0.
0
0.
9
A
C
E
in
hi
bi
to
rs
?
T
H
L
D
s
?
C
C
B
s?
6.
0
7.
7
2.
0
3.
2
1.
0
0.
4
0.
0
0.
2
A
R
B
s
?
C
C
B
s
?
be
ta
bl
oc
ke
rs
11
.0
6.
6
0.
0
2.
8
1.
0
0.
8
0.
0
0.
3
A
C
E
in
hi
bi
to
rs
?
A
R
B
s
?
C
C
B
s
2.
0
1.
9
0.
0
0.
8
1.
0
0.
4
0.
0
0.
2
A
C
E
in
hi
bi
to
rs
?
PS
D
s
?
be
ta
bl
oc
ke
rs
0.
0
0.
4
1.
0
0.
2
0.
0
0.
8
2.
0
0.
7
A
R
B
s
?
T
H
L
D
s
?
C
C
B
s
11
.0
8.
9
0.
0
3.
7
3.
0
3.
4
3.
0
2.
8
B
et
a
bl
oc
ke
rs
?
C
C
B
s
?
lo
op
di
ur
et
ic
s
1.
0
1.
9
0.
0
0.
8
1.
0
0.
3
0.
0
0.
2
A
R
B
s
?
PS
D
s
?
lo
op
di
ur
et
ic
s
1.
0
0.
4
0.
0
0.
2
0.
0
0.
3
1.
0
0.
2
Diabetes Ther (2018) 9:1853–1868 1863
combination with PSDs was observed at the last
visit. On the other hand, THLDs combined with
either CCBs or beta blockers showed only a
weak association with low DBP and diastolic
hypotension across most of the visits.
Analysis of the associations of the triple
antihypertensive medications with low DBP
and diastolic hypotension was carried out, and a
summary of the results is presented in Table 6.
Those results reveal strong and significant
associations (V4, p\ 0.01) of low DBP and
diastolic hypotension with the following com-
binations of antihypertensive medications: (1)
ACE inhibitors and THLDs and PSDs, (2) ARBs
and THLDs and PSDs, and (3) ARBs and beta
blockers and PSDs. This observation was con-
fined to V4, but the combination of ARBs with
THLDs and beta blockers showed an association
trend at V3. In addition, THLDs used in com-
bination with CCBs and either ACE inhibitors
or ARBs showed a tendency to cause low DBP
and diastolic hypotension (Table 6).
DISCUSSION
It is well documented that obesity, DM, and
hypertension are key elements in the develop-
ment of adverse cardiovascular outcomes [20].
Interestingly, a meta-analysis of some random-
ized controlled trials and observational studies
questioned the involvement of obesity as a
main factor in the enhanced mortality rate due
to cardiovascular complications. This phe-
nomenon is called the ‘‘obesity paradox’’ [21].
Follow-up studies have shown that prolonged
and intensive use of medications following
revascularization by percutaneous coronary
intervention provides a reasonable explanation
for the obesity paradox [22]. Although tight
control of the SBP is crucial to avoiding or
minimizing these adverse outcomes, various
opinions have been reported regarding the
potential link of constricted SBP with diastolic
dysfunction [23, 24].
The principal finding of the present study is
that antihypertensive therapies tended to lower
the DBP and cause diastolic hypotension in
obese Emirati patients with T2DM. In agree-
ment with previous reports, the present study
demonstrated that antihypertensive monother-
apy treatment strategies include ACE inhibitors,
ARBs, CCBs, beta blockers, and THLDs [25].
However, additional antihypertensive classes,
such as loop diuretics, DRIs, and PSDs were also
used as monotherapies to treat hypertension in
this group of patients. It is noteworthy that
PSDs were used as an alternative to classical
antihypertensive options late in the treatment
course. Compared to the other monotherapy
treatments that were used, ACE inhibitors and
ARBs showed significant associations with a low
DBP and diastolic hypotension, suggesting that
renin–angiotensin–aldosterone system blockade
may have negative effects on diastolic function.
In contrast, the latter was investigated in the
Left Ventricular Mass and Diastolic Function
(ELVERA) trial, and an improvement in diastolic
function in response to lisinopril treatment was
reported. It is important to note that this trial
was conducted in hypertensive patients who
had already been diagnosed with diastolic dys-
function prior to the trial [26]. Other trials have
also reported that ACE inhibitors and ARBs
produced reductions in vasoconstriction and
cardiac volume load and therefore significantly
improved diastolic hypotension. Those trials
were conducted in different populations,
including Swedish and Chinese, using different
hypertensive subclasses. Conflicting data were
subsequently published that led to doubt over
the prognostic beneficial effects of ACE inhibi-
tors and ARBs on diastolic function [27–29].
These doubts were supported by the findings of
some trials conducted over long periods,
including the Irbesartan in Heart Failure with
Preserved Ejection Fraction trial (one-year fol-
low-up) and the Candesartan in Heart Failure
trial (three-year follow-up), which showed that
neither irbesartan nor candesartan produced a
benefit over placebo in cardiovascular outcomes
[30, 31].
The study reported in this paper was a non-
interventional study conducted in Emirati
T2DM patients. None of those patients had
previously been diagnosed with diastolic dys-
function, which may explain the difference in
diastolic pressure outcomes between this study
and the other studies.
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In good agreement with previous reports, the
results of the present study fail to demonstrate
any association of CCBs with low DBP or dias-
tolic hypotension. It was previously found that
CCBs help to maintain healthy diastolic func-
tion by attenuating calcium homeostasis, slow-
ing the heart rate, and improving several
diastolic parameters at the one- and two-year
follow-up visits, suggesting superior prognostic
effects to ACE inhibitors and ARBs [26, 32].
Similarly, the findings of the present study
show that the use of diuretics (PSDs, THLDs,
and loop diabetics) as monotherapies for short
or long periods in the studied population did
not produce a pronounced reduction in the
DBP; this was also the case for DRIs. Although
the effects of diuretics on hypertension have
been studied in depth, very few reports have
investigated the role of these antihypertensive
agents in DBP. Those reports, along with the
results of the present study, suggest that the use
of diuretics in hypertensive patients does not
adversely affect diastolic function [28, 33].
It has been found that a combined antihy-
pertensive treatment is key to achieving opti-
mal control of the BP and maintaining quality
of life, and 75% of patients who achieved these
targets were on combined therapies [34].
Another important finding of the present study
is that dual therapy of ACE inhibitors with
either THLDs or CCBs or beta blockers was sig-
nificantly associated with a low DBP and dias-
tolic hypotension. Although it seems that ACE
inhibitors combined with THLDs produce sim-
ilar effects to ACE inhibitors combined with
beta blockers, other studies have demonstrated
that the latter combination is more effective
and has safer endpoints when used as an initial
combination therapy [25]. In addition, the
present study found that ACE inhibitors in
combination with ARBs or diuretics (including
PSDs or loop diuretics) were not associated with
diastolic parameters.
Interestingly, a significant association pat-
tern was observed with low DBP and diastolic
hypotension when the antihypertensive treat-
ment was a combination of ARBs with THLDs or
CCBs. Furthermore, other combinations of
ARBs with beta blockers and loop diuretics were
significantly associated with a low DBP but not
with diastolic hypotension. However, these
combinations did show association trends with
a low DBP and diastolic hypotension when used
later in the treatment course.
Although the American Society of Hyperten-
sion identified a group of antihypertensive
combinations (ACE inhibitors with beta blockers
and ARBs with beta blockers) as being less effec-
tive at controllinghigh blood pressure [34], these
combinations seemed to be effective at lowering
the DBP in the present study population.
The evaluation of the effects of triple anti-
hypertensive therapies on DBP performed in the
present study demonstrated that ACE inhibitors
or ARBs with diuretics (THLDs or PSDs) and beta
blockers are significantly associated with a low
DBP (74–64 mmHg). However, none of the tri-
ple antihypertensive combinations were associ-
ated with diastolic hypotension. This may lead
to doubt over the finding that tight hyperten-
sion control using multiple antihypertensive
medications always leads to diastolic hypoten-
sion in elderly patients. An alternative expla-
nation is that the effects of antihypertensive
therapies on diastolic function depend mainly
on the medicine classes used, not the number of
medications. This statement is supported by the
results of the Avoiding Cardiovascular Events
Through Combination Therapy in Patients Liv-
ing With Systolic Hypertension Trial, which
showed that triple therapy was more efficient at
controlling BP and produced safer cardiovascu-
lar outcomes [35].
It is important to note that the main differ-
ence between the present study and previous
studies is that the population studied in this
work were obese patients with hypertension
and T2DM. It has been shown that T2DM is one
of the main factors that can lead to unexpected
outcomes concerning the effects of antihyper-
tensive therapies and diastolic function [36]. In
addition, it has been observed that ethnicity
influences how the antihypertensive medica-
tions affect DBP, so it is important to note the
homogeneity of the population studied in the
present work (all patients were Emiratis) [37].
In agreement with previous reports, the
present study found that triple therapy with
ARBs, ACE inhibitors, and CCBs had a good
safety profile, and no correlation of this triple
Diabetes Ther (2018) 9:1853–1868 1865
therapy with a low DBP or diastolic hypoten-
sion has been reported [38].
International guidelines for controlling
hypertension have recommended targets, SPB/
DBP\130/80 mmHg, for hypertensive patients
with T2DM. These are 10 mmHg lower than the
targets for antihypertensive patients with nor-
mal glycemia (SPB/DBP\ 140/90 mmHg)
[39, 40]. Taking into account the outcomes of
the present study, it seems reasonable to utilize
the same concept and propose a cutoff value for
diastolic hypotension in patients with T2DM.
In this group of patients, we propose that dias-
tolic hypotension should be defined as a DBP of
less than 70 mmHg, which is 10 mmHg higher
than the previously specified level (60 mmHg).
One of the main limitations of the present
study is the small sample size for each group.
The small sample sizes occurred because only
patients for whom the clinical parameters of
interest were recorded at all visits were accep-
ted. In addition, it was important to differenti-
ate between low diastolic pressure and diastolic
hypotension using different categories. This
limitation could be overcome in the future by
including a larger sample at the beginning of
the study.
CONCLUSION
The present study investigated various subclasses
of antihypertensive medications and their asso-
ciations with lowDBP and diastolic hypotension
in T2DM patients for the first time. A significant
association of monotherapy using ACE inhibi-
tors or ARBs with low DBP or diastolic hypoten-
sion was observed. The same associative pattern
was observed for dual antihypertensive therapies
using ACE inhibitors and THLDs, CCBs, or beta
blockers. Triple antihypertensive combinations
including ACE inhibitors or ARBs plus diuretics
(THLDs or PSDs) and beta blockers were signifi-
cantly associated with low DBP but not with
diastolic hypotension. These results provide new
insights into how diastolic hypotension should
be defined and aid the formulation of recom-
mendations for obese Emirati patients with
T2DM. Further investigations of the relation-
ships between antidiabetic medications and
diastolic hypotension should lead to a better
understanding of this type of hypotension in
T2DM patients.
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